News

Ikarovec Advances Series A Fundraising with Strong Momentum

Company releases updated corporate deck highlighting preclinical superiority, regulatory progress, and compelling investment opportunity

Norwich, UK – 22/10/2025 – Ikarovec Limited today announced the release of its updated corporate presentation in conjunction with the company’s ongoing Series A fundraising round. The comprehensive deck showcases recent milestones, preclinical data demonstrating superiority versus complement-only approaches, and the company’s clinical development strategy for IKAR-001.

“We’ve made substantial progress since initiating our Series A process,” said Thomas Ciulla, MD, MBA, President and CEO of Ikarovec. “With 25% of our $46 million round already verbally committed, positive FDA feedback, manufacturing underway, and our Australian clinical trial application advancing, we’re well-positioned to bring our differentiated dual-pathway gene therapy to patients with geographic atrophy.”

Recent Milestones:

• Series A Progress: $46M round, 25% verbally committed, targeting Q1 2026 close
• Regulatory Advancement: Positive FDA feedback; Australian CTN application in progress
• Manufacturing: GMP production underway with experienced AAV8 CDMO partner
• Scientific Validation: World-class SAB assembled; strong reception at AAO EyeCelerator showcase
• Competitive Positioning: Preclinical data demonstrate IKAR-001’s superiority versus single-pathway approaches

The updated corporate presentation is available at [link].

Investment Opportunity

Ikarovec is advancing a de-risked dual-pathway gene therapy platform with near-term value inflection points, including IND approval and Phase I/IIa trial initiation. The company’s approach builds on validated complement modulation pathways while adding neuroprotection—designed to preserve vision, not just slow disease progression.

With a large addressable market (5M GA patients, gene-agnostic extension to 1.5M RP patients), proven management team, and platform expansion opportunities in wet AMD and intermediate AMD, Ikarovec offers investors multiple value creation pathways.

Connect with Ikarovec

Investors interested in learning more about the Series A opportunity can meet with the Ikarovec team at LSX Investival on November 17th or throughout London Life Sciences Week (November 16-21). To schedule a meeting or request additional information, please contact [email/contact info].

About Ikarovec

Ikarovec is pioneering dual-pathway gene therapies for retinal degenerative diseases. The company’s proprietary bicistronic platform enables the expression of two synergistic therapeutic proteins from a single gene therapy vector, addressing multiple disease pathways simultaneously.

Led by an experienced management team with proven exits including Luxturna (Spark Therapeutics, $4.8B to Roche), Izervay (Iveric Bio, $5.9B to Astellas), and EyeBio ($3.0B to Merck), Ikarovec is backed by LifeArc Ventures, Parkwalk Advisors, and UKI2S.

For more information, visit www.ikarovec.com or follow us on LinkedIn.